Physician profile
Nitin A Patel
NPI 1336323989
$1,489.92
in general payments reported to CMS, 2019-2025
13 companies · $319 in 2025
The $319 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $111 · 2020: $86.10 · 2021: $353 · 2022: $168 · 2023: $206 · 2024: $246 · 2025: $319.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $741 · Education: $30.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $740.66 |
| Education | $30.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $673.67 | 2019-2025 | |
| Janssen Biotech, INC. | $333.59 | 2019-2025 | Tremfya, Stelara, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $146.78 | 2019-2025 | Xifaxan |
| Boston Scientific Corporation | $90.91 | 2024 | Exalt Model D |
| Pfizer INC. | $58.04 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $55.06 | 2019-2023 | Entyvio |
| Gilead Sciences, INC. | $32.78 | 2023 | |
| Nestle Healthcare Nutrition INC. | $25.15 | 2021 | |
| Alk-Abello, INC | $17.82 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $15.42 | 2024 | Dupixent |
| Alfasigma USA, INC. | $14.25 | 2022 | |
| Phathom Pharmaceuticals, INC. | $14.07 | 2025 | Voquezna |
| Daiichi Sankyo INC. | $12.38 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nitin Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.